Enhancer polymorphisms at the IKZF1 susceptibility locus for acute lymphoblastic leukemia impact B-cell proliferation and differentiation in both Down syndrome and non-Down syndrom...

por Gant, Vincent U., Junco, Jacob J., Terrell, Maci, Rashid, Raushan, Rabin, Karen R.
Publicado 2021

Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency

por Perez, Monika W., Sias-Garcia, Oscar, Daramola, Alfred, Wei, Helen, Terrell, Maci, Rashid, Raushan, Park, Woojun D., Duong, Kevin, Horton, Terzah M., Li, Feng, Cherayil, Nikitha, Koren, Jost Vrabic, Gant, Vincent U., Junco, Jacob J., Curry, Choladda V., Stevens, Alexandra M., Lin, Charles Y., Yi, Joanna S.
Publicado 2021

Ex Vivo Drug Sensitivity Correlates with Clinical Response and Supports Personalized Therapy in Pediatric AML

por Strachan, Debbie C., Gu, Christine J., Kita, Ryosuke, Anderson, Erica K., Richardson, Michelle A., Yam, George, Pimm, Graham, Roselli, Jordan, Schweickert, Alyssa, Terrell, Maci, Rashid, Raushan, Gonzalez, Alan K., Oviedo, Hailey H., Alozie, Michelle C., Ilangovan, Tamilini, Marcogliese, Andrea N., Tada, Hiroomi, Santaguida, Marianne T., Stevens, Alexandra M.
Publicado 2022

Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated

por Stevens, Alexandra McLean, Schafer, Eric S., Li, Minhua, Terrell, Maci, Rashid, Raushan, Paek, Hana, Bernhardt, Melanie B., Weisnicht, Allison, Smith, Wesley T., Keogh, Noah J., Alozie, Michelle C., Oviedo, Hailey H., Gonzalez, Alan K., Ilangovan, Tamilini, Mangubat-Medina, Alicia, Wang, Haopei, Jo, Eunji, Rabik, Cara A., Bocchini, Claire, Hilsenbeck, Susan, Ball, Zachary T., Cooper, Todd M., Redell, Michele S.
Publicado 2023